Patients with the high expression of YAP1 in pancreatic cancer have a poor prognosis than those with the low expression (MST: 394 vs. 691 days, P < 0.0001) (Figure 7(a)); YAP1 expression has no significant effect on overall survival in gastric cancer (MST: 801 vs. 1043 days, P=0.756) (Figure 5(b)). This evidence concerns the gene YAP1 and familial pancreatic carcinoma.